Varex Imaging Corp Q3 2025 Earnings Call Highlights: Revenue Beats Guidance Amid Mixed Segment Performance
ByAinvest
Wednesday, Aug 13, 2025 3:09 pm ET1min read
VREX--
Despite the positive signs, total revenue was down 3% YoY, with the medical segment declining by 4%. Operating expenses were unusually high at $148 million, primarily due to a non-cash goodwill impairment charge of $94 million. This resulted in an operating loss of $81 million and a net loss of $89 million on a GAAP basis [1].
The company successfully paid off $200 million in convertible notes, reducing overall debt and simplifying the capital structure. Sales in China were better than forecasted, with a 4% YoY increase, contributing 15% of total revenues [2].
Varex Imaging Corp's Chief Executive Officer, Sunny Sanyal, expressed optimism about the continued adoption of its systems in cargo inspection applications and a healthy demand environment for both Medical and Industrial segments to drive sales growth of approximately 3% for fiscal year 2025 [1].
References:
[1] https://www.vareximaging.com/news/varex-announces-financial-results-for-third-quarter-fiscal-year-2025/
[2] https://ca.finance.yahoo.com/news/varex-imaging-corp-vrex-q3-074119601.html
Varex Imaging Corp reported Q3 2025 revenue of $203mln, exceeding guidance. The industrial segment showed strength, with a 1% YoY increase in revenue. Non-GAAP gross margin was 34%, surpassing expectations. However, total revenue was down 3% YoY, with the medical segment declining by 4%. Operating expenses were unusually high, resulting in an operating loss of $81mln and a net loss of $89mln on a GAAP basis.
Varex Imaging Corp (Nasdaq: VREX) reported its unaudited financial results for the third quarter of fiscal year 2025, revealing a mixed performance. The company reported revenue of $203 million, exceeding the high end of its guidance. The industrial segment showed strength, with a 1% year-over-year (YoY) increase in revenue. However, the company's non-GAAP gross margin was 34%, surpassing expectations due to higher volume and favorable product sales mix [1].Despite the positive signs, total revenue was down 3% YoY, with the medical segment declining by 4%. Operating expenses were unusually high at $148 million, primarily due to a non-cash goodwill impairment charge of $94 million. This resulted in an operating loss of $81 million and a net loss of $89 million on a GAAP basis [1].
The company successfully paid off $200 million in convertible notes, reducing overall debt and simplifying the capital structure. Sales in China were better than forecasted, with a 4% YoY increase, contributing 15% of total revenues [2].
Varex Imaging Corp's Chief Executive Officer, Sunny Sanyal, expressed optimism about the continued adoption of its systems in cargo inspection applications and a healthy demand environment for both Medical and Industrial segments to drive sales growth of approximately 3% for fiscal year 2025 [1].
References:
[1] https://www.vareximaging.com/news/varex-announces-financial-results-for-third-quarter-fiscal-year-2025/
[2] https://ca.finance.yahoo.com/news/varex-imaging-corp-vrex-q3-074119601.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet